C12N 2760/20251
Methods of production or purification of viral material
C12N2760/20251 (Methods of production or purification of viral material) appears on 26 US grants and 52 published applications in this corpus.
Search patents in C12N- Granted patents
- 26
- Published applications
- 52
- Assignees
- 26
- Inventors
- 98
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 3 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 0 | 2 |
| 2011 | 1 | 1 |
| 2012 | 1 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 2 | 1 |
| 2016 | 1 | 2 |
| 2017 | 3 | 3 |
| 2018 | 2 | 5 |
| 2019 | 2 | 1 |
| 2020 | 5 | 3 |
| 2021 | 0 | 1 |
| 2022 | 2 | 3 |
| 2023 | 1 | 3 |
| 2024 | 2 | 8 |
| 2025 | 3 | 2 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- VSV rescue7 Jul 2026US 12,674,143 B2Boehringer Ingelheim International GmbH
- Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses14 Oct 2025US 12,440,525 B2Ottawa Hospital Research Institute
- Enhanced virus-like particles and methods of use thereof for delivery to cells3 Jun 2025US 12,319,938 B2President and Fellows of Harvard College
- Compositions and methods for viral sensitization14 Jan 2025US 12,195,451 B2Ottawa Hospital Research Institute and University of Ottawa
- Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses3 Sep 2024US 12,076,353 B2Ottawa Hospital Research Institute
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Dissociable envelope binding proteins and uses thereof30 Jul 2026US 2026/0217786 A1CSL Behring GmbH
- Stabilization of virus-based therapeutic agent14 May 2026US 2026/0130983 A1Elarex Inc.
- Process for producing a purified rhabdovirus from cell culture26 Mar 2026US 2026/0085294 A1Boehringer Ingelheim International GmbH
- Enhanced virus-like particles and methods of use thereof for delivery to cells22 Jan 2026US 2026/0022349 A1The General Hospital Corporation
Most cited
By later US patents
- Compositions and methods for enhancing virus efficacy5US 8,940,291 B2Ottawa Hospital Research Institute · 2015
- Purification processes for isolating purified vesicular stomatitis virus from cell culture4US 7,875,446 B2Wyeth · 2011
- Compositions and methods for viral sensitization2US 10,654,839 B2Ottawa Hospital Research Institute · 2020
- Pathogen restriction factors2US 8,993,318 B2The Brigham and Women S Hospital, Inc. · 2015
- Bioreactor production of virus from adherent cells1US 10,851,350 B1Genelux Corporation · 2020